LILACS – Literatura Latinoamericana y del Caribe de Ciencias de la Salud | LILACS

Results: 25

Biopsias endoscópicas en la era de la inmunoterapia y oncogenética: ¿podemos cumplir los requerimientos?

Gastroenterol. latinoam; 35 (2), 2024
Pancreatic ductal adenocarcinoma has increased its incidence in recent years. In approximately half of the cases, the diagnosis is made when the disease is in the metastatic stage. In advanced stages, treatment with immunotherapy is included with promising results. Histopathological diagnosis is required...

Development, Histological, and Ultrastructural Evaluation of Sheep Hyperimmune Serum Therapy for COVID-19

Int. j. morphol; 41 (6), 2023
SUMMARY: In response to the threat posed by new variants of SARS-CoV-2 and the urgent need for effective treatments in the absence of vaccines, the aim of this study was to develop a rapid and cost-effective hyperimmune serum (HS) derived from sheep and assess its efficacy. The utilization of a halal-cer...

Terapia com células CAR-T: reprogramação celular para o combate de neoplasias malignas

As células CAR-T são linfócitos geneticamente modificados para reconhecerem um espectro amplo de antígenos de superfície celulares. Além disso, atacam células tumorais malignas, que expressam esses antígenos, por meio da ativação da coestimulação citoplasmática, secreção de citocinas, citÃ...

Anti-PD-1 and anti-PD-l1 antibodies as immunotherapy against cancer: a structural perspective

Rev. invest. clín; 73 (1), 2021
ABSTRACT Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand-1 (PD-L1), play key roles in the suppression of the cytotoxic activity of T cells. PD-L1 is overexpressed on various types of cancer cells, leading to immune evasion. In the past decade, therapeutic antibodies that ta...

PD-1 blockade as a future treatment for colorectal cancer with microsatellite instability

ABSTRACT Introduction: Colorectal cancer is the third most common cancer worldwide, with about 15% of these tumours related with microsatellite instability, which confers distinct characteristics to these tumours, both clinicopathological and in the response to treatments. In fact, the poor response to ...

Los ensayos clínicos en la ruta del cáncer a la cronicidad
Clinical trials in the way of cancer to a chronic disease

Rev. medica electron; 42 (5), 2020
RESUMEN El cáncer es actualmente uno de los problemas de salud más importantes en la mayoría de los países occidentales. En Cuba, el cáncer es la segunda causa de muerte para todos los grupos de edad superada solo por las enfermedades cardiovasculares. En Matanzas, en los últimos años el cáncer h...

Efectividad de inducción de tolerancia inmune en niños con hemofilia A y aloanticuerpos neutralizantes

Rev. chil. pediatr; 91 (2), 2020
Resumen: Introducción: El desarrollo de aloanticuerpos neutralizantes anti-factor VIII en hemofilia A es la complicación más seria relacionada al tratamiento. La inducción de tolerancia inmune (ITI) o inmunotolerancia es el único tratamiento que erradica inhibidores, permitiendo utilizar nuevament...

Clinical characteristics of primary extranodal versus nodal diffuse large B-Cell Lymphoma: A retrospective cohort study in a cancer center

Rev. invest. clín; 71 (5), 2019
Background The outcome of patients with primary extranodal diffuse large B-cell lymphoma (PE-DLBCL) varies according to the primary site involved. Primary gastrointestinal, breast, bone, craniofacial, and testicular DLBCL are rare extranodal manifestations of DLBCL. Objective The objective of the study ...

Pemphigus vulgaris

An. bras. dermatol; 94 (3), 2019
Abstract: Pemphigus vulgaris is a chronic autoimmune bullous dermatosis that results from the production of autoantibodies against desmogleins 1 and 3. It is the most frequent and most severe form of pemphigus, occurring universally, usually between 40 and 60 years of age. It usually begins with blisters...

Inmunoterapia en cáncer: Perspectivas actuales, desafíos y nuevos horizontes
Immunotherapy in cancer. Current prospects, challenges and new horizons

Medicina (B.Aires); 78 (5), 2018
La activación del sistema inmunológico en pacientes con cáncer ha sido un objetivo histórico en el campo de la oncología. En las últimas décadas, nuestro entendimiento de la respuesta inmunológica antitumoral ha promovido el desarrollo de novedosas estrategias terapéuticas dando como resultado u...